Pulmonx Q3 revenue $17.7M record +31% YoY; raises FY2023 guidance to $67-68M

Pulmonx Corp

2023-Q3 EPS reported -$1.24 revenue$49,397,000

Record worldwide revenue $17.7M (+31% YoY); U.S. revenue $11.8M (+41% YoY).
Net loss $14.9M ($0.39 EPS) vs $14.2M ($0.38 EPS) in Q3 2022.
Raised 2023 revenue guidance to $67-68M (prior $64-66M); gross margin ~74%.
Adjusted EBITDA loss improved to $9.0M from $9.7M YoY.
Japan MHLW approved Zephyr Valve reimbursement for severe COPD/emphysema.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pulmonx Corp reported the third quarter of 2023 ended September 30, 2023 results: revenue $17.7 million, net income $14.9 million, EPS $0.39 per share. Guidance raised.

Period: the third quarter of 2023 ended September 30, 2023
Revenue: $17.7 million
Net income: $14.9 million
EPS: $0.39 per share
Guidance: raised
Result: reported results

Exact text from the filing

Total worldwide revenue in the third quarter of 2023 was $17.7 million

View on SEC.gov

Browse all earnings releases →

Pulmonx Corp filing history →

Source: SEC EDGAR

accession 0001127537-23-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.